Anthera, When IPOs Go Awry (ANTH)
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) is a very unusual Monday IPO. The fact that it is being viewed as a dud has little to do with the day of the week. Late last week, Anthera cut the expected price range…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
This drop is just a lack of interest. The company is not profitable and for all practical purposes has no drugs on the market. Deutsche Bank Securities was the book-runner, and other underwriters were Piper Jaffray, Cowen & Co., and Merriman Curhan Ford.
The company is preparing to begin a pivotal Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome – 16 Weeks). This is its lead product candidate, called A-002. The product is an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
While its R&D expenses dropped nearly two-thirds in the last two years, there is effectively no revenue. Its loss applicable was $12.2 million in 2009. We do not have an accurate or set time-table to see how long it will be before an actual FDA approval process will start after a new drug application is filed.
The good news is that the pricing was low enough that it did not trade as a busted deal. Shares are actually up 3.5% at $7.25 and about 450,000 shares have traded hands since this opened for trading just over an hour ago.
Jon C. Ogg
Contact [email protected] for any questions or corrections.
Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.
McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.
His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.
A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.
TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.
McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.
